Effects of Danshensu on Platelet Aggregation and Thrombosis: In Vivo Arteriovenous Shunt and Venous Thrombosis Models in Rats

Chen Yu¹,², Dong Qi²,³, Wei Lian³, Qing-Zhong Li³, Hong-Juan Li¹, Hua-Ying Fan⁴*

¹ School of Pharmacy, Binzhou Medical University, Yantai, Shandong, China, ² Department of Nephrology, Yantai Yu-Huang-Ding/Qingdao University Hospital, Yantai, Shandong, China, ³ Yantai Yan-Tai-Shan Hospital, Yantai, Shandong, China, ⁴ School of Pharmacy, Yantai University, Yantai, Shandong, China

Abstract

Danshensu, a type of dihydroxyphenyl lactic acid, is one of the most abundant active phenolic acids in the dried root of Salvia miltiorrhiza (Lamiaceae)—widely used traditional Chinese medicine. The effects of danshensu on platelet aggregation and thrombus formation in rats were examined using various methods. It was found that danshensu significantly reduced thrombus weight in 2 experimental thrombosis models; dose-dependent inhibition of adenosine diphosphate (ADP) and arachidonic acid (AA)-induced platelet aggregation occurred in normal and blood stasis-induced rats; Danshensu also significantly mitigated blood viscosity, plasma viscosity and hematocrit levels. Moreover, danshensu significantly inhibited venous thrombosis-induced expression of cyclooxygenases-2 (COX-2) rather than cyclooxygenases-1 (COX-1) in the venous walls, down regulated thromboxane B2 (TXB2) and up regulated 6-keto prostaglandin F1a (6-keto-PGF1α), normalizing the TXB2/6-keto-PGF1α ratio. In addition, danshensu did not induce gastric lesions and even had protective effects on aspirin-induced ulcer formation at doses as high as 60 mg/kg. These findings suggest that the antithrombotic and antiplatelet aggregation effects of danshensu are attributed to its highly selective inhibition of COX-2 and ability to normalize the thromboxane A2 (TXA2)/prostacyclin (PGI2) balance. These findings suggest that danshensu have great prospects in antithrombotic and antiplatelet therapy.

Introduction

Thrombus formation accelerates the progression of various cardiovascular and cerebrovascular disorders. Thromboembolic complications of arteriosclerosis, heart attack, stroke and peripheral vascular disease are the principal causes of death in developed countries. Arterial and venous thrombi comprises primarily platelet aggregates. Platelets mediate the initiation of thrombosis through platelet adhesion, activation and aggregation [1]. A collaborative meta-analysis of randomized trials has demonstrated that antiplatelet therapy is beneficial in treating thromboembolic diseases and preventing serious vascular events, arterial occlusion and venous thromboembolism in a wide range of patients who are at high risk for occlusive vascular events [2]. Thus, the inhibition of platelet function has the potential to treat circulatory diseases, spurring the development of many antiplatelet and antithrombotic agents and prompting an examination of their effects in preventing thrombosis.

Danshen, the dried root of Salvia miltiorrhiza (Lamiaceae), is one of the most widely used traditional herbal medicines against various cardiovascular and cerebrovascular diseases, including coronary heart disease, myocardial infarction, stroke and hypertension. Danshen contains hydrophilic phenolics and lipophilic quinones, which have many pharmacological and therapeutic properties [3].

Increasing data have demonstrated that danshensu is an abundant and representative phenolic acid in danshen [4]. Danshensu (chemical structure shown in Fig. 1)—known as β-3,4-dihydroxyphenyl-lactic acid—has several mechanisms by which it elicits its therapeutic effects. Danshensu can mitigate cardiovascular and cerebrovascular disturbances [5] by improving microcirculation, increasing blood flow, relaxing the coronary arteries and promoting anticoagulation [6].

However, the antithrombotic and antiplatelet effects and mechanisms of danshensu are unknown. The purpose of this study was to determine the effects and mechanisms of danshensu with regard to platelet aggregation, thrombus formation and blood circulation so as to provide pharmacological evidence that supports its clinical application.
Effects on platelet aggregation in vivo

To assess the effect of danshensu on platelet aggregation, we measured the inhibition of platelet aggregation on danshensu induced by ADP and AA in normal rats. As shown in Fig. 2, compared with the control group, ADP and AA-induced platelet aggregation was altered by pretreatment with danshensu and aspirin. Danshensu dose-dependently inhibited AA-induced platelet aggregation by approximately 13.9% at 15 mg/kg, 17.9% at 30 mg/kg and 21.5% at 60 mg/kg, respectively. This result showed that similar inhibition in the ADP-induced platelet aggregation. The inhibition of platelet aggregation induced by ADP was 10.5%, 14.6% and 23.5% at doses of 15, 30, and 60 mg/kg, respectively.

Further, we determined effect of danshensu on platelet aggregation in blood stasis rats induced by AA. Blood stasis increased platelet aggregation compared with the control group as shown in Fig. 3, which was also modified by pretreatment with danshensu in a dose-dependent manner. This inhibitory effect of danshensu at dose of 60 mg/kg was comparable with that of aspirin at 20 mg/kg.

Effect on thrombus formation

Two rat models of thrombosis were developed by installing an arteriovenous shunt and ligating the inferior vena cava to study the antithrombotic activity and mechanism of danshensu in vivo. Pretreatment with danshensu (15 to 60 mg/kg) decreased thrombus formation dose-dependently in the arteriovenous shunt model. The inhibition of thrombus formation was about 12.6%, 18.2% and 29.6% respectively (Fig. 4).

As shown in Fig. 5, this result was confirmed by inferior vena cava model. Residual thrombi from the occlusive vessels of all rats were measured. Compared with the thombotic control group, aspirin at 20 mg/kg decreased the thrombus weight from 35.37±3.03 mg to 24.14±2.23 mg versus 29.65±5.62 mg with 15 mg/kg, 25.78±3.95 mg with 30 mg/kg and 23.54±2.26 mg with 60 mg/kg of danshensu, respectively. Antithrombotic activity of danshensu at dose of 60 mg/kg is comparable with that of aspirin at 20 mg/kg.

Effects on COX and possible mechanisms

Inhibitory effects of danshensu and aspirin against 2 cyclooxygenases (COX) isoforms were first examined in vitro using enzymatic assays. While danshensu had little inhibitory effect on COX-1, danshensu decreased COX-2 activity at 20 to 200 μM even at 200 μM yielding an IC_{50} value of approximately 44 μM (Fig. 6 A vs B).

In contrast, aspirin inhibited COX-1 and COX-2, with geometric mean IC_{50} values of 39.8 and 60.7 μM, respectively. The IC_{50} ratios of COX-1 to COX-2 for danshensu and aspirin exceeded 10 and 0.67 respectively, it is demonstrated that danshensu selectively inhibits COX-2 over COX-1 by approximately 20-fold.

The effects of danshensu on COX-1 and COX-2 levels were examined using western blot technique. As shown in Fig. 7, the expression of COX-1 and COX-2 induced by inferior vena cava ligation was significantly elevated when compared with control group. It is clear that aspirin significantly inhibited both COX-1 and COX-2 expression while danshensu only significantly inhibited COX-2 but not COX-1 expression (Fig. 7B vs D). This observation indicates that danshensu exerts its antiplatelet effect by selectively targeting on COX-2.

Next, we measured the serum concentrations of TXB2 and 6-keto-PGF1α in the rats. TXB2 and 6-keto-PGF1α levels increased significantly, accompanying a rise in the TXB2/6-keto-PGF1α ratio.

Figure 1. Chemical structure of danshensu (C_{9}H_{10}O_{5}, molecular weight = 198.17).
doi:10.1371/journal.pone.0110124.g001

Figure 2. Effect of danshensu on platelet aggregation in normal rats. Blood was drawn 60 min after intragastric danshensu administration. Platelet aggregation was induced by diphosphate (ADP) and arachidonic acid (AA). Data are expressed as mean ± SEM (each group, n = 10). **P < 0.01 with control group.
doi:10.1371/journal.pone.0110124.g002
ratio in the 2 thrombosis models. Aspirin significantly reduced TXB$_2$ and 6-keto-PGF$_{1\alpha}$ levels, decreasing the TXB$_2$/6-keto-PGF$_{1\alpha}$ ratio. Danshensu downregulated TXB$_2$ and increased 6-keto-PGF$_{1\alpha}$ levels, especially at 30 and 60 mg/kg, normalizing the TXB$_2$/6-keto-PGF$_{1\alpha}$ ratio better than aspirin (Tables 1 and 2).

**Effect on hemorheology**

Whole blood viscosity (WBV) at all shear rates, plasma viscosity (PV) and hematocrit values (Hct) significantly rose in blood stasis rats, but danshensu significantly reduced blood viscosity, plasma viscosity and hematocrit, particularly at 30 and 60 mg/kg (Table 3).

**Protective effects of danshensu on gastric mucosa**

We examined the gastrointestinal (GI) effects of oral administration of danshensu and aspirin in rats for 7 days. The ulcer index for all groups is summarized in Fig. 8. Aspirin resulted in gastric lesions and the ulcer index was significantly higher than the control group. In contrast, danshensu did not induce gastric lesions, even at as high as 60 mg/kg.

We also investigated the effect of danshensu on aspirin-induced gastric lesions. The macroscopic findings of open stomachs are shown in Fig. 9A, we found that oral administration of aspirin (200 mg/kg body weight) induced severe mucosal damage in the gastric corpus of mice. Danshensu had no damaging effects on the stomach. In addition co-administration of danshensu with aspirin could inhibit aspirin-induced ulcer formation. Fig. 9B shows the ulcer score of gastric hemorrhagic ulcers in each group. These data suggest that danshensu has gastroprotective activities and it also prevents aspirin-induced gastric ulcer formation.

**Discussion**

Many life-threatening diseases, such as atherosclerosis, cerebrovascular thrombosis, coronary artery disease, stroke and tumor metastasis are related with platelet dysfunctions [7]. Many

---

**Figure 3. Effect of danshensu on platelet aggregation in blood stasis rats.** Blood was drawn 60 min after intragastric danshensu administration. Platelet aggregation was induced by arachidonic acid (AA). Data are expressed as mean ± SEM (each group, n = 10). The blood stasis model was built during the interval between when 2 injections of adrenaline hydrochloride (Adr) were given to rats placed in ice-cold water. **##P<0.01 compared with normal control. *P<0.05 **P<0.01 compared with Adr control. doi:10.1371/journal.pone.0110124.g003**

**Figure 4. Antithrombotic activity of danshensu in the rat model of arteriovenous shunt.** The drug or solvent was administered orally 60 min before thrombogenic challenge. Data are expressed as mean ± SEM (each group, n = 10). Thromb: thrombosis. *P<0.05, **P<0.01, ***P<0.001 compared with thrombotic control group. doi:10.1371/journal.pone.0110124.g004
available antiplatelet agents interfere with platelet function at various levels of activation, which results in several clinical disadvantages, including gastrointestinal side effects and hemorrhage. For this reason, a search for safer and more effective antiplatelet agents without these adverse effects would be highly desirable. In recent years, new therapeutic agents have been derived from Chinese herbs and there is growing interest in this area.

In this study, we examined the antiplatelet and antithrombotic effects of danshensu and the pharmacological mechanisms. We determined effects of danshensu on platelet function by measuring ADP and AA-induced platelet aggregation. Our results showed that danshensu produced marked antiplatelet effect on ADP and AA platelet agonists ex vivo aggregation. This inhibitory effect of danshensu at dose of 60 mg/kg was comparable with aspirin at 20 mg/kg in blood stasis-induced rats.

The effects of danshensu on thrombus formation were studied in arteriovenous shunt model and inferior vena cava model; these models simulate arterial and venous thrombosis observed in humans [8]. Our results demonstrated that danshensu has potent antithrombotic effects against arterial and venous thrombosis.

To assess the effect of danshensu on microcirculation, we evaluated hemorheologic parameters in blood stasis model. Blood stasis can result in platelet aggregation and hemorheological abnormalities. Hemorheological disorders mediate the pathogenesis and development of many cardiovascular and cerebrovascular diseases [9]. In this study, rats were injected subcutaneously with adrenaline hydrochloride (Adr) and treated with cold stress. As a result, blood viscosity, plasma viscosity and hematocrit increased significantly compared with the control group. Our results suggest that Adr combined with exposure to ice-cold water induces blood stasis resulting in hemorheological abnormalities. Platelet aggregation is believed to be a factor that determines blood viscosity [10], consistent with our results that danshensu improves hemorheologic parameters, ameliorates blood stasis and promotes circulation by decreasing whole blood viscosity, secondary to the inhibitory effect on platelet aggregation.

In our study, Danshensu exhibited apparent antiplatelet and antithrombotic activity. In order to explore the further mechanisms of antiplatelet and anti-thrombosis, the activity and expression of COXs were measured. We also evaluated the levels of TXB2 and 6-keto-PGF1α in both arterial and venous thrombosis models. Our results indicated that danshensu could selectively inhibit COX-2 rather than COX-1 to regulate the balance of TXA2/PGI2. Therefore, danshensu exhibited superior antiplatelet and antithrombotic effects compared with aspirin.
Disruption of the TXA2-PGI2 balance increases the risk of thrombosis [11]. TXA2 and PGI2 are metabolites of arachidonic acid, which is hydrolyzed by COXs and transformed into endoperoxides, prostaglandins (PGs) and TXA2 [12]. COXs exist as 2 distinct isoforms: COX-1 and COX-2. COX-1 which is constitutively expressed in most tissues and has high levels of activity in the gastrointestinal tract, is thought to exert homeostatic properties that are crucial for gastric physiologic function, including mucosal protection whereas COX-2 is absent from most healthy tissues but is induced by proinflammatory and proliferative stimuli after exposure to cytokines, immunological stimuli and growth factors [13,14]. TXA2 is a potent inducer of platelet aggregation and vasoconstriction and its levels rise in thrombus models. In contrast, PGI2 is a potent platelet inhibitor. An increase in TXA2 results in the adhesion, aggregation and release of platelets. However, PGI2 inhibits platelet aggregation [15,16]. In our study, aspirin significantly decreased both TXB2 and 6-keto-PGF1a levels due to its non-selective and irreversible COX inhibition. Aspirin exerts its antiplatelet activity through inhibition of both COX-1 and COX-2, therefore inhibits not only the production of TXA2 in platelets, but also the production of anti-aggregatory PGI2 in vessel walls. This phenomenon is referred to as the “aspirin dilemma”[17] and is considered to be a reason underlying the insufficient efficacy and unclear dose–response effects of aspirin [18,19]. Compared with aspirin, danshensu with higher selectivity for COX-2 is able to normalize the TXA2/PGI2 balance better, by upregulating 6-keto-PGF1a and downregulating TXB2 simultaneously.

Finally, we evaluated the protective effects of danshensu on gastric mucosa. We compared the ulcerogenic effects of danshensu and aspirin on gastric mucosa and demonstrated that danshensu did not cause any apparent ulceration of the gastric mucosa in rats, even at a dose of 60 mg/kg. In contrast, aspirin had a potent ulcerogenic effect at the antithrombotic dose (20 mg/kg) and produced severe hemorrhagic necrotic lesions in the gastric mucosa even at a dose of 200 mg/kg. Aspirin-induced gastric lesion was completely inhibited by the coadministration of danshensu. The observed differences in gastric ulcerogenic properties between danshensu and aspirin may be related with the difference in COX-1 selectivity. COX-1-derived PGs are thought to play a dominant role in gastric mucosal defense and cytoprotection and it has been confirmed that selective inhibition of COX-1 alone may not cause ulcers, but inhibition of both COX-1 and COX-2 is required for the development of gastric lesions [20,21]. Thus, danshensu by selectively inhibit COX-2 only, is considered to be potentially less damaging to the gastrointestinal tract than aspirin that also block COX-1.

In conclusion, our findings suggest that danshensu has potent antithrombotic effects and antiplatelet aggregation activity without inducing GI adverse events. This might be attributed to danshensu’s mechanism of its functions as a highly selective COX-2 inhibitor with an ability to normalize TXA2/PGI2 balance superior to aspirin. Thus, Danshensu may have good prospects in antithrombotic and antiplatelet therapy.

### Materials and Methods

**Chemicals and reagents**

Danshensu (purity 98%) was provided by Nanjing Zelang Medical Biological Technology Co. Ltd (Nanjing, China). Aspirin (purity 98%) was produced by Anhui Fengyuan Pharmaceutical Co. Ltd (Anhui, China). Arachidonic acid (AA) was purchased from Sigma-Aldrich Chemical Co. (USA). Heparin sodium was purchased from Jiangsu Wanbang Biochemical Medicine Co. Ltd. (Jiangsu, China). Adrenaline hydrochloride was purchased from Tianjin Jinyao Amino Acids Co. Ltd. (Tianjin, China). COX inhibitor screening assay kits were purchased from Cayman Chemical Company (Ann Arbor, MI, USA). Primary antibodies against COX-1, COX-2, β-actin and horseradish peroxidase (HRP)-conjugated secondary antibody were purchased from Santa Cruz Biotechnology, Inc. The thromboxane B2 (TXB2) and 6-keto prostaglandin F1a (6-keto-PGF1a) radioimmunoassay kits were produced by Tianjin Juding Engineering of Medicine and Biology Co. Ltd. (Tianjin, China).

**Animals and treatments**

Male Sprague-Dawley rats (weight approximately 300 g, 3–4 months each) were purchased from Shandong Lvye Pharmacu-
**Table 1.** Effects of danshensu on plasma TXB\(_2\) and 6-keto-PGF\(_{1\alpha}\) levels and TXB\(_2\)-6-keto-PGF\(_{1\alpha}\) ratio in rats in the arteriovenous shunt model.

| Group            | Dose (mg/kg) | TXB\(_2\) (pg/mL) | 6-keto-PGF\(_{1\alpha}\) (pg/mL) | TXB\(_2\)/6-keto-PGF\(_{1\alpha}\) |
|------------------|--------------|-------------------|---------------------------------|----------------------------------|
| Normal           |              | 180.0±8.3         | 487.3±16.6                      | 0.38±0.01                        |
| Thromb           |              | 552.2±18.9***     | 602.5±20.4***                   | 0.93±0.03**                      |
| Thromb+Aspirin   | 20           | 565.6±19.9***     | 190.5±7.5***                    | 0.30±0.01***                     |
| Thromb+Danshensu | 15           | 258.1±10.2**      | 621.7±19.8*                     | 0.40±0.01**                      |
|                  | 30           | 228.7±11.5**      | 638.3±22.1**                    | 0.37±0.02**                      |
|                  | 60           | 206.4±8.9**       | 649.2±15.8**                    | 0.35±0.02**                      |

Blood was drawn from the abdominal aorta at the end of arteriovenous shunt test period and anticoagulated with indomethacin-EDTA-Na\(_2\). Data are expressed as mean±SEM (each group, n = 10). *P<0.05, **P<0.01, ***P<0.001 compared with normal group, #P<0.05, ##P<0.01 compared with thrombotic control group.

doi:10.1371/journal.pone.0110124.t001

**Table 2.** Effects of danshensu on plasma TXB\(_2\) and 6-keto-PGF\(_{1\alpha}\) levels and TXB\(_2\)-6-keto-PGF\(_{1\alpha}\) ratio in rats the venous thrombosis model.

| Group            | Dose (mg/kg) | TXB\(_2\) (pg/mL) | 6-keto-PGF\(_{1\alpha}\) (pg/mL) | TXB\(_2\)/6-keto-PGF\(_{1\alpha}\) |
|------------------|--------------|-------------------|---------------------------------|----------------------------------|
| Normal           |              | 197.0±8.2         | 528.3±16.8                      | 0.37±0.03                        |
| Thromb           |              | 605.2±21.9***     | 652.5±24.6***                   | 0.95±0.03**                      |
| Thromb+Aspirin   | 20           | 106.5±4.2***      | 395.0±14.5***                   | 0.29±0.01***                     |
| Thromb+Danshensu | 15           | 358.1±12.8**      | 663.7±24.2*                     | 0.50±0.02**                      |
|                  | 30           | 328.7±10.6**      | 684.3±25.1**                    | 0.45±0.02**                      |
|                  | 60           | 306.4±8.2***      | 719.2±20.9**                    | 0.40±0.02**                      |

Blood was drawn from the abdominal aorta at the end of venous thrombus formation period and anticoagulated with indomethacin-EDTA-Na\(_2\). Plasma samples were prepared by centrifugation and analyzed by radioimmunoassay. Data are expressed as mean±SEM (each group, n = 10). *P<0.05, **P<0.01, ***P<0.001 compared with thrombotic control group.

doi:10.1371/journal.pone.0110124.t002

**In vivo arteriovenous shunt thrombosis**

Rat arterial-venous shunts (silk thread model) were prepared with 2 2-cm-long polyethylene tubes (1 mm i.d.,) linked by a central section (8 cm long; 2 mm i.d.) that contained a 5-cm piece of silk thread and was filled with saline solution that contained heparin 50 U/kg. Rats were anesthetized with chloral hydrate (350 mg/kg, i.p.) and an arterial-venous shunt was placed between the right carotid artery and left jugular vein [22,23]. After blood was circulated through the shunt for 15 minutes, both ends of the tube were pinched, the silk thread was removed from the shunt tube and the wet and dry weights were measured by subtracting the pre-experiment weight of the 5-cm silk thread. The rate of inhibition of thrombosis formation was calculated as inhibition (%) = (A-A\(_1\))/A×100%, where A is the thrombus weight of the thrombosis control group and A\(_1\) is the weight after treatment with the agents. The sham group did not undergo the surgery. All rats fasted overnight before the operation.

**Venous thrombosis model**

Venous thrombus formation was induced by inferior vena cava (IVC) ligation to produce a stasis thrombus as described [24,25].
Rats were anesthetized with chloral hydrate (350 mg/kg, i.p.). After the rats were fixed on a temperature-controlled heating pad (38°C) to maintain body temperature, the abdomen was opened surgically. The intestines were moved gently to one side and covered with saline-moistened gauze and the vena cava was exposed by blunt dissection. One millimeter above the bifurcation of the vena iliaca and vena cava, the free vein was ligated by tightening the proximal and distal segments using 4-0 suture (Shinva Medical, China) to induce blood stasis. The abdominal cavity was closed provisionally and blood stasis was maintained for 4 h. After the abdomen was reopened, the ligated venous segment was excised and opened longitudinally to remove the thrombus. The vein wall and thrombus were divided by blunt or sharp dissection. The isolated thrombus was blotted of excess blood and weighed immediately. Harvested vein samples were homogenized for subsequent biochemical analysis. Sham operation was performed in the control group.

Measurement of plasma TXB$_2$ and 6-keto-PGF$_{1a}$

Blood was drawn from the abdominal aorta at the end of the arteriovenous shunt test period or venous thrombosis model. Plasma was prepared by centrifuging blood at 4000 rpm for 5 min. TXA$_2$ and PGI$_2$ levels were estimated by measuring their stable hydrolysis products—TXB$_2$ and 6-keto-PGF$_{1a}$, respectively—per standard procedures using EIA kits (Cayman Chemical) and expressed as pg/mL.

### Table 3. The effect of danshensu on the hemorheological parameters in rats.

| Group          | WBV(mPa.s) Low shear rate | WBV(mPa.s) Medium shear rate | WBV(mPa.s) High shear rate | PV(mPa.s) | Hct(%) |
|----------------|---------------------------|------------------------------|----------------------------|-----------|--------|
| Normal Control | 22.72±1.21                | 5.88±0.25                   | 4.44±0.11                  | 1.41±0.08 | 0.41±0.02 |
| Adr Control    | 39.55±1.35**              | 9.01±0.32**                 | 6.52±0.23**               | 2.06±0.06** | 0.45±0.02** |
| Adr Aspirin 20 mg/kg | 26.59±0.87**             | 6.82±0.21**                 | 5.02±0.19**               | 1.66±0.06* | 0.44±0.04 |
| Adr Danshensu 15 mg/kg | 35.36±2.25**             | 8.64±0.51**                 | 6.28±0.31**               | 1.89±0.08* | 0.45±0.02* |
| Adr Danshensu 30 mg/kg | 31.24±1.08**             | 7.74±0.23**                 | 5.65±0.18**               | 1.67±0.09* | 0.44±0.02* |
| Adr Danshensu 60 mg/kg | 27.12±1.05**             | 6.65±0.19**                 | 4.78±0.12**               | 1.45±0.42** | 0.43±0.02* |

Rats were treated by subcutaneous injection of adrenaline hydrochloride and cold stress. The normal control rats received only saline. Next, blood was collected 30 min after drug administration. Hemorheologic parameters were analyzed by routine laboratory assays. Data are expressed as mean±SEM (each group, n = 10). #P<0.05, ##P<0.01 compared with normal control. *P<0.05 **P<0.01 compared with Adr control. Adr: adrenaline hydrochloride, WBV: whole blood viscosity, PV: plasma viscosity, Hct: hematocrit.

doi:10.1371/journal.pone.0110124.t003

Rats were anesthetized with chloral hydrate (350 mg/kg, i.p.). After the rats were fixed on a temperature-controlled heating pad (38°C) to maintain body temperature, the abdomen was opened surgically. The intestines were moved gently to one side and covered with saline-moistened gauze and the vena cava was exposed by blunt dissection. One millimeter above the bifurcation of the vena iliaca and vena cava, the free vein was ligated by tightening the proximal and distal segments using 4-0 suture (Shinva Medical, China) to induce blood stasis. The abdominal cavity was closed provisionally and blood stasis was maintained for 4 h. After the abdomen was reopened, the ligated venous segment was excised and opened longitudinally to remove the thrombus. The vein wall and thrombus were divided by blunt or sharp dissection. The isolated thrombus was blotted of excess blood and weighed immediately. Harvested vein samples were homogenized for subsequent biochemical analysis. Sham operation was performed in the control group.

Measurement of plasma TXB$_2$ and 6-keto-PGF$_{1a}$

Blood was drawn from the abdominal aorta at the end of the arteriovenous shunt test period or venous thrombosis model. Plasma was prepared by centrifuging blood at 4000 rpm for 5 min. TXA$_2$ and PGI$_2$ levels were estimated by measuring their stable hydrolysis products—TXB$_2$ and 6-keto-PGF$_{1a}$, respectively—per standard procedures using EIA kits (Cayman Chemical) and expressed as pg/mL.
Effects of Danshensu on COX activity and expression

The inhibition of COX-1 and COX-2 by danshensu and aspirin was determined using COX inhibitor screening assay kits per the manufacturer’s instructions. Danshensu and aspirin (with the same volume of water serving as control) were incubated directly with COX-1 or COX-2 in reaction buffer for 10 min. Then, AA was added as substrate and the reaction continued for another 2 min. Then, 0.1 N HCl and saturated stannous fluoride solution were added immediately to stop the enzymatic reaction. The amount of prostaglandin E2 (PGE$_2$) that was generated by COX was measured using Cayman ELISA kits. The effects of danshensu and aspirin on COX activity were evaluated by comparing the amounts of PGE$_2$ production between reactions with and without the drugs. Inhibitory rates were calculated, based on PGE$_2$ production, as follows: Inhibitory rate (%) = (PGE$_2$ in Control groups-PGE$_2$ in drug-treated groups) ×100/PGE$_2$ in Control groups.

To measure COX-1 and COX-2 expression, venous walls from the venous thrombosis were analyzed by western blot. Venous samples were homogenized mechanically on ice and centrifuged at 4500 g for 10 minutes at 4°C; total proteins were then collected from the supernatants and the protein content was measured using a BCA protein assay kit.

Samples were separated by SDS-PAGE for immunoblot analysis. After the electrophoresis running for 60 min, proteins were transferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked with 3% skim milk and saturated in Tris-buffered saline with 1% Tween 20 for 1 h at room temperature. Then, the membrane was incubated with primary anti-COX-1 and anti-COX-2 (1:300; Cayman Chemical) overnight at 4°C. The membranes were washed three times for 5 min each and incubated in horseradish peroxidase (HRP)-conjugated secondary antibody solution for 1 h at room temperature. The blots were washed again and visualized by using an enhanced chemiluminescence (ECL) detection kit (Beyotime Institute of Biotechnology) and exposure to photographic film. Images were collected and the respective bands were quantitated by densitometric analysis using the DigDoc100 program.

Effects of danshensu on blood stasis

The blood stasis model was established per previous reports [26]. The rats were divided randomly into 6 groups of 10 rats each: normal control, model group given 0.9% normal saline, aspirin (20 mg/kg) and Danshensu (15, 30 and 60 mg/kg). All drugs and saline were administered orally to the rats once per day at 9 AM for 7 days. After the sixth administration, blood stasis was induced by placing the rats in ice-cold water between 2 injections of adrenaline hydrochloride (Adr). All other rats were injected subcutaneously with Adr (0.8 mg/kg), except the control rats, which were injected with 0.9% (w/v) NaCl saline solution. Two hours after the first injection, all rats except the control group were soaked in ice water (0-2°C) for 5 min and reinfected with Adr (0.8 mg/kg) subcutaneously 2 h later to effect blood stasis. Afterward, the rats were placed into cages and fed freely.

Blood samples were collected and anticoagulated with heparin 30 min after the last administration of drugs or saline on the following day. Hemorheologic parameters, including WBV at various shear rates, PV and Hct, were measured by routine laboratory assays. Another aliquot of blood was collected into plastic tubes that contained 3.8% citrate and prepared PRP and PPP as described in Assay of ex Vivo Platelet Aggregation in Rats. Platelet aggregation was measured by arachidonic acid-induced.

Ucerogenic Effects of Danshensu on Gastric Mucosa

Rats were sacrificed by cervical dislocation and the stomachs were removed immediately to determine the gastric ulcer index after the platelet aggregation assays described with modifications [27,28]. The stomach tissues were split longitudinally and opened along the greater curvature. The total length (mm) of visible mucosal lesions in each stomach sample was measured and used to establish an ulcer index. An independent observer scored the macroscopic appearance of the gastric mucosa. The ulcer area was calculated as $\pi/4 \times a \times b$ mm$^2$, where $a$ is the long axis and $b$ is the short axis. The ulcer area was expressed as an ulcer index.

Effects of danshensu on aspirin-induced gastric lesion in mice

To investigate the effect of danshensu on aspirin-induced gastric lesions, male ICR mice were randomly divided into 4 groups. Group 1 received 1% carboxymethylcellulose in water as vehicle, Group 2 received danshensu treatment (120 mg/kg body weight), Group 3 received aspirin treatment (200 mg/kg body weight, suspended in 1% carboxymethylcellulose in water) and Group 4 received treatment of aspirin and danshensu. All drugs were administered orally once per day at 9 AM for 7 days. The mice were anesthetized with ether and sacrificed. One hour after the last administration, the isolated stomachs were dissected and the gastric mucosa were stained with hematoxylin and eosin, and the macroscopic pictures were captured. The stomachs were cut along the greater curvature and the lengths of lesions on the stomach wall were measured as described [29].

Statistical analysis

Data were analyzed using SigmaStat 3.1 (SPSS Inc.; Chicago, IL) and expressed as mean±standard error of means (SEM). $P<0.05$ was considered to be statistically significant.

Acknowledgments

Chen Yu and Dong Qi contributed equally to this work.

Author Contributions

Conceived and designed the experiments: CY DQ. Performed the experiments: CY DQ. Analyzed the data: WL QZL HJL. Contributed reagents/materials/analysis tools: HJL HYF. Wrote the paper: CY DQ.

References

1. Ruggeri ZM, Loretana Mendolicchio G (2007) Adhesion Mechanisms in Platelet Function Circulation Research. 100:1673–1685.
2. Antithrombotic Trials’ Collaboration. (2002) Collaborative meta-analysis of randomised-trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 324:71–86.
3. Kang DG, Oh H, Sohn EJ, Hur TY, Lee KC, et al. (2004) Lithospermic acid B isolated from Salviae miltiorrhiza ameliorates ischaemia/reperfusion-induced renal injury in rats. Life Sci. 75: 1001–1010.
4. Chan K, Chui SH, Wong DY, Ha WY, Chan CL, et al (2004) Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (danshen) against homocysteine-induced endothelial dysfunction, Life Sci. 75: 3157–3171.
5. Zhao GR, Zhang HM, Ye XN, Xiang ZZ, Yuan YJ, et al (2008) Characterization of the radical scavenging and antioxidant activities of Danshensu and salvianolic acid B. Food and Chemical Toxicology. 46: 73–81.
6. Chan K, Chui SH, Wong DY, Ha WY, Chan CL, et al (2004) Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Dansen) against homocysteine-induced endothelial dysfunction. Life Sciences. 75: 3157–3171.
7. Tran H, Anand SS (2004) Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease and peripheral arterial disease. J Am Med Assoc. 292: 1867–1874.
8. Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haerlein BJ, et al (2001) Antiplatelet and Antithrombotic Activity of RWJ-53308, A Novel Orally Active Glycoprotein IIb/IIIa Antagonist. Thromb Res. 104: 113–126.
9. Nosar’ R, Jancinova V (2002) Cationic amphiphilic drugs and platelet phospholipase A2 (cPLA2). Thromb Res. 106: 339–345.
10. Ryu KH, Han HY, Lee SY, Jeon SD, Im GJ, et al (2009) Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thrombosis Research. 124: 328–334.
11. Baskurt OK, Meiselman HJ (2003) Blood Rheology and Hemodynamics. Semin Thromb Hemost. 29: 435–450.
12. Takeuchi K (2012) Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World J Gastroenterol. 18(31): 4547–4553.
13. Halter F, Tarnawski AS, Schmassmann A (2001) Cyclooxygenase 2—implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 49: 443–449.
14. Masferrer JL, Zweifel BS, Seibert K (1990) Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest. 86: 1373–1379.
15. Lechi C, Andrioli G, Gaino S, Tommasoli R, Zuliani V, et al (1996). The antiplatelet effects of a new nitroderivative of acetylsalicylic acid—an in vitro study of inhibition on the early phase of platelet activation and on TXA2 production. Thrombosis and Haemostasis. 76(3): 791–798.
16. Weiss HJ, Turitto VT (1979) Prostaglandin (prostaglandin E2, PGJ2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood. 53(2): 244–250.
17. Patrone C, Garcia Rodriguez LA, Landolfi R, Baigent C (1979) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 333(22): 2373–2378.
18. Collaboration AT (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 324 (7329): 71–86.
19. Sakata C, Kawasaki T, Kato Y, Abe M, Suzuki K, et al (2013) ASP5637, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without “aspirin dilemma”. Thrombosis Research. 132: 56–62.
20. Wooten JG, Blikslager AT, Ryan KA, Marks ML, Law JM, et al (2000) Cyclooxygenase expression and prostanooid production in pyloric and duodenal mucosae in dogs after administration of nonsteroidal anti-inflammatory drugs. Am J Vet Res. 69(4): 457–64.
21. Wallace JL, McKnight W, Reuter BK, Vergnolle N (2000) NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology. 119: 706–14.
22. Umar A, Boisecou M, Yunup Az, Begaud B, et al (2004). Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. Fundam Clin Pharmacol. 18(5): 559–563.
23. Unosbeau M, Garreau C, Begaud B, Mollaret M, Moore N (2003) Effects of armagnac extracts on human platelet function in vitro and on rat arteriovenous shunt thrombosis in vivo. Thromb Res. 110: 135–140.
24. Henke PK, Varga A, De S, Dearthick CB, Eliaou J, et al (2004). Deep vein thrombosis resolution is modulated by monocyte CXCR2-mediated activity in a mouse model. Arteriother Thromb Vasc Biol. 24: 1130–1137.
25. Henke PK, Varma MR, Deswery KB, Deswery NA, Lynch EM, et al (2006) Neutrophils modulate post-thrombotic vein wall remodeling but not thrombus neovascularization. Thromb Haemost. 2006; 95: 272–281.
26. Chen XP, Wang XY, Zhang YY, Xu XF, Ke WB, et al (2007) Effect of ethanol extract of terminalia chebula on microcirculatory characteristics in acute blood stasis model rat. Chin J Histochem. 17(4): 323–329.
27. Sakata C, Kawasaki T, Kato Y, Abe M, Suzuki K, et al (2013) ASP5637, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without “aspirin dilemma”. Thrombosis Research. 132: 56–62.
28. Mei XT, Xu DH, Xu SK, Zheng YP, Xu SB (2013) Zinc(II)-curcumin accelerates the healing of acetic acid-induced chronic gastric ulcers in rats by decreasing oxidative stress and downregulating matrix metalloproteinase-9. Food and Chemical Toxicology. 60: 448–454.
29. Guth PH, Auers D, Paulsen G (1989) Topical aspirin plus HCl gastric lesion in the rat. Gastroenterology. 76: 88–90.